GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

NCT03576612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma, Malignant

Interventions

BIOLOGICAL: AdV-tk
DRUG: Valacyclovir
RADIATION: Radiation
DRUG: Temozolomide
BIOLOGICAL: Nivolumab
OTHER: Laboratory Biomarker Analysis

Sponsor

Candel Therapeutics, Inc.

Collaborators

[object Object]
[object Object]